CGRP

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine

By

Researchers assessed the ability of erenumab to decrease the mean number of acute headache days in patients with episodic migraine.

Positive Results for Ubrogepant in Phase 3 Migraine Trial

Positive Results for Ubrogepant in Phase 3 Migraine Trial

By

A total of 1,327 migraine patients were treated in the study for a single migraine attack. At 2 hours after migraine attack, 19.2% (n=423) and 21.2% (n=448) of ubrogepant 50mg and 100mg were pain free, respectively.

Erenumab Shows Promise in Treatment-Resistant Migraine

Erenumab Shows Promise in Treatment-Resistant Migraine

By

A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.

CGRP Antagonist Shows Effectiveness in Acute Migraine

CGRP Antagonist Shows Effectiveness in Acute Migraine

By

Allergan has announced positive Phase 3 trial results for ubrogepant, a novel calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine.

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

Erenumab for Episodic Migraine Prophylaxis: Current Evidence

By

The monoclonal antibody erenumab has shown favorable results regarding efficacy and safety for the prevention of migraine.

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

By

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

Implication of the Microbiota in Migraine Pathogenesis

Implication of the Microbiota in Migraine Pathogenesis

By

Migraineurs process nitrate- and nitrite-containing foods differently than the general population.

Sign Up for Free e-Newsletters